Compare USFD & ILMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | USFD | ILMN |
|---|---|---|
| Founded | 2007 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Food Distributors | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.1B | 18.9B |
| IPO Year | 2016 | 2000 |
| Metric | USFD | ILMN |
|---|---|---|
| Price | $78.68 | $131.13 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 11 | 15 |
| Target Price | $88.36 | ★ $114.93 |
| AVG Volume (30 Days) | ★ 2.2M | 2.1M |
| Earning Date | 11-06-2025 | 10-30-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 2.09 | N/A |
| EPS | 2.38 | ★ 4.46 |
| Revenue | ★ $39,115,000,000.00 | $4,288,000,000.00 |
| Revenue This Year | $6.54 | N/A |
| Revenue Next Year | $6.01 | $2.22 |
| P/E Ratio | $32.99 | ★ $29.47 |
| Revenue Growth | ★ 4.80 | N/A |
| 52 Week Low | $57.36 | $68.70 |
| 52 Week High | $85.11 | $153.06 |
| Indicator | USFD | ILMN |
|---|---|---|
| Relative Strength Index (RSI) | 66.77 | 70.96 |
| Support Level | $69.88 | $117.86 |
| Resistance Level | $71.97 | $126.94 |
| Average True Range (ATR) | 1.66 | 4.29 |
| MACD | 0.99 | 0.32 |
| Stochastic Oscillator | 95.68 | 92.04 |
US Foods Holding Corp is the U.S. food service distributor that distributes food and nonfood products to the healthcare and hospitality industries, restaurants, and education, government facilities, and grocers. It has nearly 250,000 restaurants and foodservice operators with more than 70 locations that provide customers with food offering and a comprehensive suite of e-commerce, technology, and business solutions. The company operates in one business segment in which it markets, sells and distributes fresh, frozen and dry food and non-food products to foodservice customers throughout the U.S.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.